These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26711755)

  • 1. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
    Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
    Bhavnani SM; Rubino CM; Ambrose PG; Drusano GL
    Clin Infect Dis; 2010 Jun; 50(12):1568-74. PubMed ID: 20462352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
    Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
    Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.
    Butterfield JM; Mueller BA; Patel N; Cardone KE; Grabe DW; Salama NN; Lodise TP
    Antimicrob Agents Chemother; 2013 Feb; 57(2):864-72. PubMed ID: 23208714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.
    Moise PA; Amodio-Groton M; Rashid M; Lamp KC; Hoffman-Roberts HL; Sakoulas G; Yoon MJ; Schweitzer S; Rastogi A
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1192-200. PubMed ID: 23254428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
    Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis.
    Prabhudesai S; Kanjani A; Nambi PS; Gnanasambandam S; Ramachandran B
    Pediatr Infect Dis J; 2016 May; 35(5):517-8. PubMed ID: 27074655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
    Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S
    Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis.
    Durante-Mangoni E; Casillo R; Bernardo M; Caianiello C; Mattucci I; Pinto D; Agrusta F; Caprioli R; Albisinni R; Ragone E; Utili R
    Clin Infect Dis; 2012 Feb; 54(3):347-54. PubMed ID: 22100575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.
    Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA
    Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM; Rojtman AD
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG
    Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
    Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
    Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
    Segreti JA; Crank CW; Finney MS
    Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.
    Baxi SM; Chan D; Jain V
    Infection; 2015 Dec; 43(6):751-4. PubMed ID: 25805524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
    J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.